Skip to main content
Have a personal or library account? Click to login
DNA and histone deacetylases as targets for neuroblastoma treatment Cover

DNA and histone deacetylases as targets for neuroblastoma treatment

Interdisciplinary Toxicology
Volume 3 (2010): Issue 2 (June 2010)
By: ,  ,  ,   and    
Open Access
|Jul 2010
References

References

  1. Auclair C. (1987). Multimodal action of antitumor agents on DNA: The ellipticine series.: 1-14.
    Search in Google Scholar
  2. Bader P, Schilling F, Schlaud M, Girgert R, Handgretinger R, Klingebiel T, Treuner J, Liu C, Niethammer D and Beck JF. (1999). Expression analysis of multidrug resistance associated genes in neuroblastomas.: 1143-1146.
    Search in Google Scholar
  3. Bates SE, Shieh CY and Tsokos M. (1991). Expression of mdr-1/P-glycoprotein in human neuroblastoma.: 305-315.
    Search in Google Scholar
  4. Bedrnicek J, Vicha A, Jarosova M, Holzerova M, Cinatl J Jr, Michaelis M, Cinatl J and Eckschlager T. (2005). Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.: 415-419.
    Search in Google Scholar
  5. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW and Cinatl J Jr. (2007). Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.: 1699-706.
    Search in Google Scholar
  6. Bolden JE, Peart MJ and Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors.: 769-784.
    Search in Google Scholar
  7. Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma.: 203-216.
    Search in Google Scholar
  8. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M and Boccuzzi G. (2006). Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.: 465-472.
    Search in Google Scholar
  9. Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, Yu Y, Wang H, McNutt MA, Hu YG, Chen Y, Yang Y, Wu X, Otterson GA and Zhu WG. (2008). HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.: e2445.
    Search in Google Scholar
  10. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW and Kornhuber B. (1996). Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.: 766-773.
    Search in Google Scholar
  11. de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, Vielh P and Michon J. Role of chemotherapy resistance genes in outcome of neuroblastoma. (2007).: 311-317.
    Open DOISearch in Google Scholar
  12. Emanuel SL, Chamberlin HA and Cohen D. (1999). Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells.: 487-494.
    Search in Google Scholar
  13. Fossé P, René B, Charra M, Paoletti C and Saucier JM. (1992). Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships.: 590-595.
    Search in Google Scholar
  14. Froelich-Ammon SJ, Patchan MW, Osheroff N and Thompson RB. (1995). Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.: 4998-5004.
    Search in Google Scholar
  15. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A and Frühwald MC. (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.: 1787-1794.
    Search in Google Scholar
  16. Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M and Skálová L. (2008). Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.: 9-18.
    Search in Google Scholar
  17. Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL and Gross N. (2002). Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.: 6132-37.
    Search in Google Scholar
  18. Hooven LA, Mahadevan B, Keshava C, Johns C, Pereira C, Desai D, Amin S, Weston A and Baird WM. (2005). Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a] pyrene DNA adduct formation in human cells.: 1283-1287
    Open DOISearch in Google Scholar
  19. Hřebačková J, Poljaková J, Eckschlager T, Hraběta J, Procházka P, Smutný S and Stiborová M. (2009). Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.: 205-210.
    Search in Google Scholar
  20. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F. (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.: 7291-7300.
    Search in Google Scholar
  21. Klener P. (1996).(in Czech) Galén, Praha.
    Search in Google Scholar
  22. Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J and Cinatl J Jr. (2005). Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.: 1029-1037.
    Search in Google Scholar
  23. Kucerova H, Sumerauer D, Drahokoupilova E, Piskova M, Bedrnicek J and Eckschlager T. (2001). Significance of P-glycoprotein expression in childhood malignant tumors.: 472-478.
    Search in Google Scholar
  24. Kurowski C and Berthold F. (1998). Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells.: 1009-1014.
    Search in Google Scholar
  25. Lal S, Mahajan A, Chen WN and Chowbay B. (2010). Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.: 115-128.
    Search in Google Scholar
  26. Lara-Bohórquez C, González-Cámpora R, Mendoza-García E, Ríos-Martín JJ, Pareja-Megía MJ and López-Beltrán A. (2008). TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors.: 105-112.
    Search in Google Scholar
  27. Marchion DC, Bicaku E, Daud AI, Sullivan DM and Munster PN. (2005a) Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.: 3815-3822.
    Open DOISearch in Google Scholar
  28. Marchion DC, Bicaku E, Daud AI, Sullivan DM and Munster PN. (2005b) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.: 1993-2000.
    Open DOISearch in Google Scholar
  29. Maris JM and Matthay KK. (1999). Molecular biology of neuroblastoma.: 2264-2279.
    Search in Google Scholar
  30. Maris JM, Hogarty MD, Bagatell R and Cohn SL. (2007). Neuroblastoma.: 2106-2120.
    Search in Google Scholar
  31. Marks PA, Miller T and Richon VM. (2003). Histone deacetylases.: 344-351.
    Search in Google Scholar
  32. Marks PA, Richon VM, Miller T and Kelly WK. (2004). Histone deacetylase inhibitors.: 137-168.
    Search in Google Scholar
  33. Merk HF and Jugert FK. (1991). Cutaneous NAD(P)H: quinone reductase: a xenobiotica-metabolizing enzyme with potential cancer and oxidation stress-protecting properties. Skin Pharmacol: 95-100.
    Search in Google Scholar
  34. Michaelis M, Suhan T, Cinatl J, Driever PH and Cinatl J Jr. (2004). Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo.: 1795-1799.
    Search in Google Scholar
  35. Michaelis M, Doerr HW and Cinatl J Jr. (2007). Valproic acid as anti-cancer drug.: 3378-3393.
    Search in Google Scholar
  36. Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek J Jr and Fermandjian S. (1991). DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives.: 1820-1829.
    Search in Google Scholar
  37. Morgenstern BZ, Krivoshik AP, Rodriguez V and Anderson PM. (2004). Wilms' tumor and neuroblastoma.: 78-85.
    Search in Google Scholar
  38. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M. (1996). Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.: 231-238.
    Search in Google Scholar
  39. Oesch-Bartlmowicz B and Oesch F. (2004) Modulation of mutagenicity by phosphorylation of mutagen-metabolizing enzymes.: 31-36.
    Open DOISearch in Google Scholar
  40. Otter I, Conus S, Ravn U, Rager M, Olivier R, Monney L, Fabbro D and Borner C. (1998). The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli.: 6110-6120.
    Search in Google Scholar
  41. Peaston AE, Gardaneh M, Franco AV, Hocker JE, Murphy KM, Farnsworth ML, Catchpoole DR, Haber M, Norris MD, Lock RB and Marshall GM. (2001). MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells.: 1564-1571.
    Search in Google Scholar
  42. Poljaková J, Eckschlager T, Hřebačková J, Hraběta J and Stiborová M. (2008). The comparison of cytotoxicity of anticancer drug doxorubicin and ellipticine to human neuroblastoma cells.: 186-189.
    Search in Google Scholar
  43. Poljakova J, Eckschlager T, Hrabeta J, Hrebackova J, Smutny S, Frei E, Martinek V, Kizek R and Stiborova M. (2009). The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.: 1466-1479.
    Search in Google Scholar
  44. Santini V, Gozzini A and Ferrari G. (2007). Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.: 383-393.
    Search in Google Scholar
  45. Singh MP, Hill GC, Peoch D, Rayner B, Inabach JL and Lown JW. (1994). High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine.: 10271-10285.
    Search in Google Scholar
  46. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X and Yu J. (2006). Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.: 776-784.
    Search in Google Scholar
  47. Stiborová M, Bieler CA, Wiessler M and Frei E. (2001). The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.: 675-684.
    Search in Google Scholar
  48. Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M and Frei E. (2003a) DNA adduct formation by the anticancer drug ellipticine in rats determined byP-postlabeling.: 885-890.
    Open DOISearch in Google Scholar
  49. Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. (2003b) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.: 38-47.
    Open DOISearch in Google Scholar
  50. Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M and Frei E. (2004). The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine-oxide.: 8374-8380.
    Search in Google Scholar
  51. Stiborová M, Rupertová M. Schmeiser HH and Frei E. (2006). Molecular mechanism of antineoplastic action of an anticancer drug ellipticine.: 13-23.
    Search in Google Scholar
  52. Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T and Frei E. (2007a) Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those foundand generated from 12-hydroxyellipticine and 13-hydroxyellipticine.: 243-251.
    Open DOISearch in Google Scholar
  53. Stiborová M, Rupertová M, Aimová D, Ryšlavá H and Frei E. (2007b) Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.: 50-60.
    Open DOISearch in Google Scholar
  54. Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudeček J, Phillips DH and Frei E. (2008). Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouse.: 318-327.
    Search in Google Scholar
  55. Stiborová M, Rupertová M and Frei E. (2010). Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its antitumor efficiency., in press.
    Search in Google Scholar
  56. Schwab M. (1999). Human neuroblastoma: from basic science to clinical debut of cellular oncogenes.: 71-78.
    Search in Google Scholar
  57. Uccini S, Colarossi C, Scarpino S, Boldrini R, Natali PG, Nicotra MR, Perla FM, Mannarino O, Altavista P, Boglino C, Cappelli CA, Cozzi D, Donfrancesco A, Kokai G, Losty PD, McDowell HP and Dominici C. (2006). Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours.: 49-55
    Open DOISearch in Google Scholar
  58. van Schaik R. (2005). Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.: 513-522.
    Search in Google Scholar
  59. van Schaik RH. (2008). CYP450 pharmacogenetics for personalizing cancer therapy.: 77-98
    Open DOISearch in Google Scholar
  60. Voigt A, Hartmann P and Zintl F. (2000). Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid.: 423-440.
    Search in Google Scholar
  61. Wang H and Tompkins L. (2008). CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.: 598-610.
    Search in Google Scholar
  62. Westermann F and Schwab M. (2002). Genetic parameters of neuroblastomas.: 127-147.
    Search in Google Scholar
  63. Witt O, Deubzer HE, Lodrini M, Milde T and Oehme I. (2009). Targeting histone deacetylases in neuroblastoma.: 436-447.
    Search in Google Scholar
  64. Zhu WG and Otterson GA. (2003). The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.: 187-199.
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10102-010-0010-6 | Journal eISSN: 1337-9569 | Journal ISSN: 1337-6853
Journal RSS Feed
Language: English
Page range: 47 - 52
Published on: Jul 30, 2010
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Keywords:
neuroblastoma,
DNA-damaging anticancer drugs,
inhibitors of histone deacetylases,
mechanisms of acticancer effects of drugs
Related subjects:
Medicine,
Clinical medicine,
Pharmacology, toxicology

© 2010 Marie Stiborová, Jitka Poljaková, Tomáš Eckschlager, Rene Kizek, Eva Frei, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.

Volume 3 (2010): Issue 2 (June 2010)
Previous article
Next article